Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1425-1428

  Whitacre, Cecilia M ^a   Zborowska, Elizabeth ^a   Gordon, Nahida H ^a   Mackay, Wilma ^a   Berger, Nathan A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER TRANSPLANTATION; COLON CANCER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; ETOPOSIDE; FEMALE; HUMANS; ISOENZYMES; MICE; MICE, NUDE; NEOPLASM PROTEINS; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0030937484     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wang, J. C. Interaction between DNA and an Escherichia coli protein. J. Mol. Biol., 55: 523-533, 1971.
2. Champoux, J. J. Renaturation of complementary single-stranded DNA circles: complete rewinding facilitated by the DNA untwisting enzyme. Proc. Natl. Acad. Sci. USA, 74: 5328-5332, 1877.
3. Liu, L. F., Liu, C. C., and Alberts, B. M. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell, 19: 697-707, 1980.
4. Kreuzer, K. N., and Cozzarelli, N. R. Formation and resolution of DNA catenanes by DNA gyrase. Cell, 20: 245-254, 1980.
5. Baldi, M. I., Benedetti, P., Mattoccia, E., and Tocchini-Valentini, G. P. In vitro catenation and decatenation of DNA and a novel eukaryotic ATP-dependent topoisomerase. Cell, 20: 461-467, 1980.
6. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikutnar, G., Kirschenbaum, S., Silver, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989.
7. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
8. Osheroff, N., Zechiedrich, E. L., and Gale, K. C. Catalytic function of DNA topoisomerase II BioEssays, 13: 269-273, 1991
9. Zhang, H., D'Arpa, P., and Liu, L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells (Cold Spring Harbor), 2: 23-27, 1990.
10. Berger, N. A., Chatterjee, S., Schmotzer, J. A., and Helms, S. R. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death, Proc. Natl. Acad. Sci. USA, 88: 8740-8743, 1991.
11. Potmeesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
12. Cheson, B. D., Phillips, P. H., and Arbuck, S. G. Clinical trials referral resource: trials of topotecan. Oncology Huntingt, 9: 220, 224-226, and 228, 1995.
13. Sinka, B. K. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs, 49: 11-19, 1995.
14. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 57: 1129-1136, 1991.
15. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer, 50: 760-766, 1992.
16. Masumoto, N., Nakano, S., Esaki, T., Tatsumoto, T., Fujishima, H., Baba, E., Nakamura, M., and Niho, Y. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res., 75: 405-410, 1995.
17. Bertrand, R., O'Connor, P. M., Kerrigan, D., and Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eun J. Cancer, 28: 743-748, 1992.
18. Sorensen, M., Sehested, M., and Jensen, P. B. Characterization of a human small cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br. J. Cancer, 72: 399-404, 1995.
19. Cheng, M. F., Chatterjee, S., and Berger, N. A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol. Res., 6: 269- 279, 1994.
20. McBain, J. A., Weese, J. L., Meisner, L. F., Wolberg, W. H., and Willson, J. K. V. Establishment and characterization of human colorectal cancer cell lines. Cancer Res., 44: 5813-5821, 1984.
21. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethy-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
22. Dempke, W. C., Whelan, R. D., and Hill, B. T. Expression of resistance to etoposide and vincristine in vitro and in vivo after X-irradiation of ovarian tumor cells. Anticancer Drugs, 3: 395-399, 1992.
23. Sun, L., Wu, G., Willson, J. K. V., Zborowska, E., Yang, J., Rajkarunanayake, I., Wang, J., Gentry, L. E., Wang, X-F., and Brattain, M. G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem., 269: 26449-26455, 1994.
24. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
25. Kleinbaum, D., Kupper, L., and Muller, K. Applied Regression Analysis and Other Multivariable Models. Boston: PWS-Kent Publishing Co., 1988.
26. Berger, S. J., Tsai, M. L., Chatterjee, S., Markowitz, S. D., Willson, J. K. V., and Berger, N. A. Transcriptional down regulation of topoisomerase II relative to topoisomerase I in normal and malignant colon tissues, implications for therapy of colon cancer. Proc. Am. Assoc. Cancer Res., 34: 328, 1993.
27. Hsiang, Y-H., Liu, L. F., Hochster, H., and Potmesil, M. Levels of DNA topoisomerase I (TOPO I) and II (TOPO II) in human coloreclal carcinoma and normal colonic mucosa. Proc. Am. Assoc. Can. Res., 29: 172, 1988.
28. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silver, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 146: 1046-1048, 1989.